Aerogen

About:

Aerogen is a medical device and drug delivery company.

Website: http://www.aerogen.com

Twitter/X: Aerogen

Top Investors: European Investment Bank, Temasek Holdings, Disruptive Technologies Innovation Fund

Description:

Aerogen is an innovative medical device and drug delivery company specialising in the design, manufacture and marketing of aerosol drug delivery systems, aimed at the critical care respiratory market. Aerogen’s patented Vibronic aerosol technology is an integral part of its drug delivery systems, the technology allows drugs to be nebulized into a fine particle mist that can be absorbed through the lungs while maintaining drug integrity. Founded in Galway in 1997, Aerogen has grown to become the global leader in acute care aerosol drug delivery equipment. Today its Aerogen:registered: products play a critical role in treating patients on life-support ventilation in over 65 countries worldwide, and in the home care setting globally. Aerogen has a strong scientific focus with over 95% of its employees being graduates and post-graduates, primarily from Science and Engineering disciplines. Aerogen is an award winning company that continues to invest heavily in R&D, product design and development to evolve and extend its product range. Strategic alliances with leading Irish University research institutes enable Aerogen to leverage home-grown scientific excellence to facilitate its rapid growth.

Total Funding Amount:

39.4M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Galway, Galway, Ireland

Founded Date:

1997-01-01

Contact Email:

info(AT)aerogen.com

Founders:

Number of Employees:

251-500

Last Funding Date:

2019-12-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai